Cargando…
“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality
Borderline personality disorder (BPD) is an extremely disabling condition that affects almost every dimension of a patient’s life. The S-enantiomer of ketamine (esketamine) was approved by the Food and Drug Administration (FDA) in 2019 in conjunction with an oral antidepressant for the management of...
Autores principales: | Nandan, Neethu K, Soni, Puneet K, Parsaik, Ajay, Hashmi, Aqeel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156400/ https://www.ncbi.nlm.nih.gov/pubmed/35664413 http://dx.doi.org/10.7759/cureus.24632 |
Ejemplares similares
-
Function and Psychotherapy of Chronic Suicidality in Borderline Personality Disorder: Using the Reinforcement Model of Suicidality
por: Hennings, Johannes M.
Publicado: (2020) -
Prevalence and correlates of suicide attempts in Chinese individuals with borderline personality disorder
por: Yang, Fan, et al.
Publicado: (2022) -
Role of Oxytocin in the Pathogenesis and Modulation of Borderline Personality Disorder: A Review
por: Jawad, Muhammad Youshay, et al.
Publicado: (2021) -
Association between non-suicidal self-injury and suicidal behavior in Borderline Personality Disorder: a retrospective study
por: Iñigo, Alberdi-Páramo, et al.
Publicado: (2021) -
Beyond the Categorical Distinction Between Borderline Personality Disorder and Bipolar II Disorder Through the Identification of Personality Traits Profiles
por: Villarroel, Juana, et al.
Publicado: (2020)